Pharmaceutical Executive
When it comes to developing novel therapies from the animal kingdom, it's mostly a game of pick your poison
Thanks to the press coverage—and the graphic photos—of the heparin contamination story (see "Chinese Puzzle"), which took readers into the tiny rural workshops where raw pig intestines are both pulped for crude heparin and stripped for sausage casings, some of us have crossed pork off our menus. But deriving a lifesaving therapy from hog guts got us wondering what other modern meds come from our animal friends.
The answer, it seems, is more every day. Cows started the trend back in 1921, by offering up their pancreas to Canadian surgeon Frederick Banting for his discovery of insulin to lower blood sugar in diabetics. Banting got a Nobel Prize while Bessie got the glue factory.
Since then, researchers wishing to get out of the lab to design new drugs have generally had to bypass the local farm for more adventurous settings. That's because the best pickings in promising proteins, hormones, and molecules tend to reside not in fish, fowl, or beast but in the creepy crawlers, like tarantulas and lizards. Snakes—ugh—are very big on Mother Nature's drug development list, venom being a treasure-trove of potential medical applications. That explains why a German biotech has a high-security facility housing 30,000 vipers.
So how do scientists figure out which viper has the goods? Trial and terror?
Not so much. It seems to call for inspired inductive leaps. For example, Dr. Michael Zasloff, biomedical researcher, entrepreneur, and holder of more than 40 patents, was pondering one day why frogs can hang out in filthy water holes without getting sick. Well, their skin contains a potent antimicrobial peptide that is now called Magainin 2 and sold for research into resistance-resistant antibiotics.
Get it? Good. So now let's play Pharmazooticals. Match the creature on the left with the potential medical application on the right. –WALTER ARMSTRONG AND SARAH WHARTON
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.